Blueprint Medicines — Investor Presentation (September 2022)
24 slides from Blueprint Medicines's investor presentation, Sep 7, 2022
Slide 1: Blueprint Medicines Company Overview September 2022
BLUEPRINT MEDICINES COMPANY OVERVIEW SEPTEMBER 2022 Kristine G. Systemic mastocytosis patient © 2022 Blueprint Medicines Corporation Pioneering the Science of Time Not for promotional use.
Slide 2: Forward-looking statements
Forward - looking statements 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, to submit a supplemental new drug application ( sNDA ) to the U . S . Food and Drug Administr
Slide 3: Blueprint Medicines is a global leader in precision therapy
Blueprint Medicines is a global leader in precision therapy AYVAKIT is approved for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, inc lud ing PDGFRA D842V mutations, and adult patients with advanced SM, including aggressive SM, SM with an associate
Slide 4: Diverse drivers uniquely position Blueprint Medicines for long-term growth
Diverse drivers uniquely position Blueprint Medicines for long - term growth as a leading global precision therapy company advSM , advanced systemic mastocytosi ; EGFRm, EGFR mutant; FDA, U.S. Food and Drug Administration; non - advSM , non - advanced SM; NSCLC, non - small cell lung cancer 4 □ Earl
Slide 5: Driving near-term value in systemic mastocytosis
Driving near - term value in systemic mascytosis Cyndi N. Systemic mastocytosis patient Not for promotional use.
Slide 6: AYVAKIT is the current standard of care for advanced SM
AYVAKIT is the current standard of care for advanced SM 1. Reported data represent estimations. Analysis based on US claims data from Komodo Health. SM, systemic mastocytosis . 6 $17.3 $20.0 $28.5 Q3 2021 Q4 2021 Q1 2022 Q2 2022 $23.8 GLOBAL NET REVENUES ($, MILLIONS) BY FULL QUARTER SINCE ADVANCED
Slide 7: Retrospective analysis showed longer OS in AYVAKIT patients
Retrospective analysis showed longer OS in AYVAKIT patients, including in SM - AHN where clinical practice has historically prioritized AHN treatment A multi - center, global, observational, retrospective chart review study was conducted at 6 study sites (4 European, 2 US) to ide ntify and collect d
Slide 8: Non-advanced SM patients have high medical need despite available therapies
Non - advanced SM patients have high medical need despite available therapies 1 95% of SM cases driven by the KIT D816V mutation SYSTEMIC MASTOCYTOSIS SYMPTOMS 2 Brain fog Pruritis, flushing and pigmented skin lesions Life - threatening organ infiltration and damage Unpredictable, life - threatening
Slide 9: Non-advanced SM represents a significant medical need and potential blockbuster opportunity
Non - advanced SM represents a significant medical need, and is a potential blockbuster opportunity for AYVAKIT 9 1. Reported data represent estimations. Analysis based on US claims data from Komodo Health. SM, systemic mastocytosis; TKI, tyr osine kinase inhibitor; A/I, allergist/immunologist Not f
Slide 10: Largest clinical trial to date conducted in non-advanced SM
Largest clinical trial to date conducted in non - advanced SM Data cutoff as of June 23, 2022. QD, once daily; BSC, best supportive care; TSS, total symptom score; SD, standard deviation 10 Not for promotional use. Primary endpoint AYVAKIT 25 mg QD + BSC Placebo QD + BSC (Control) Mean change in TSS
Slide 11: AYVAKIT demonstrated significant impact on primary and key secondary endpoints
AYVAKIT demonstrated highly significant and clinically meaningful impact on the primary and all key secondary endpoints Data cutoff as of June 23, 2022. 1. One - sided p - value < 0.025 indicates statistical significance. 2. For secondary endpoints, re ductions in TSS and objective measures of mast
Slide 12: Decreases in patient-reported symptoms and objective measures of disease burden
Decreases in patient - reported symptoms and objective measures of disease burden 1. After 24 weeks, all patients had the option to cross over into Part 3 and receive treatment with AYVAKIT 25 mg QD. TSS, to tal symptom score; CI, confidence interval. 12 Mean Change in TSS [95 % CI] AYVAKIT Control
Slide 13: AYVAKIT was well-tolerated with a safety profile favorable to control
AYVAKIT was well - tolerated with a safety profile favorable to control Data cutoff as of June 23, 2022. 1. Cognitive effect AEs refer to 17 pooled terms identified across AYVAKIT clinical studies. AE , adverse event; SAE, serious adverse event; TRAE, treatment - related adverse event; ICB, intracra
Slide 14: Driving long-term value in EGFRm lung cancer and CDK2-vulnerable breast cancer
Driving long - term value in EGFRm lung cancer and CDK2 - vulnerable breast cancer Diane L. Lung cancer patient Not for promotional use.
Slide 15: Opportunities for our next-generation EGFR precision therapies
Opportunities for our next - generation EGFR precision therapies Approximate patient numbers covering major markets – US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insert ions. Internal estimates adapted from Ramalingam, et al. NEJM, 2020; Decision Resources Group: NSCLC Forec
Slide 16: Our portfolio of EGFR therapies is purpose-built to address medical needs
Our portfolio of EGFR therapies is purpose - built to address medical needs CS, C797S resistance mutation; Ex20in, activating exon 20 insertion mutations; LR, L858R activating mutation; TM, T790M resis tan ce mutation. 16 Not for promotional use. Effectively block the EGFR pathway Establish 2L+ SOC
Slide 17: Potency and selectivity enable wide therapeutic index and broad EGFR coverage
BLU - 945 potency and selectivity enable wide therapeutic index and broad EGFR coverage, with promising early clinical monotherapy data 17 a One p atient had two different DNA mutations in C797S. Note: reductions in individual variant allele fractions as shown; therefore, pa tients with multiple mut
Slide 18: Phase 1/2 trials to rapidly generate data in broad populations
Phase 1/2 trials to rapidly generate data in broad populations, informing development and registration strategies PLANNED INITIATION OF PHASE 1/2 SYMPHONY / HARMONY TRIAL COHORTS 1L 2L+ 2023 701 + ADC All comer 945 + osi LR 701 + chemo All comer 701 + osi All comer Q2 2022 945 + osi LR + CS +/ - TM
Slide 19: Opportunity to impact treatment paradigm across multiple CDK2-vulnerable cancers
Opportunity to impact the treatment paradigm for more than 100K patients across multiple CDK2 - vulnerable cancers 1 19 CDK - CYCLIN COMPLEXES REGULATE THE CELL CYCLE ABERRANT CYCLIN E (CCNE1) DRIVES CELL PROLIFERATION CDK4/6 Cyclin D CDK2 Cyclin E CDK2 Cyclin A CDK1 Cyclin A/B M G1 S G2 CELL DIVISI
Slide 20: BLU-222 is advancing toward clinical proof-of-concept
BLU - 222 is advancing toward clinical proof - of - concept CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor. 20 Multiple dose cohorts* RP2D Combo with ER antagonist – ER+/HER2 - breast Combo with CDK4/6i + ER antagonist – ER+/HER2 - breast Monotherapy – CCNE1 tumors PHASE 2 EXPANSI
Slide 21: Research platform expansion to drive innovation and expand productivity
Research platform expansion to drive innovation & expand productivity 21 KINASE PLATFORM KINASE PLATFORM NEW PLATFORMS INTEGRATED PLATFORM CURRENT CAPABILITIES TARGETED PROTEIN DEGRADATION ENHANCED PRODUCTIVITY COMPLEMENTARY & SCALABLE NEW TARGET CLASSES LIBRARY & NEW TARGET DISCOVERY EXPANSION Cons
Slide 22: Business development plays a key role in value creation and portfolio growth
Business development plays a key role in our company's value creation and long - term portfolio growth 22 Global Strategic Partnerships Access complementary expertise to maximize program value and global impact on patients Geographic Expansion Pioneering early development partnerships in China; expa
Slide 23: Strong financial position bolstered by diversity of revenue sources
Strong financial position bolstered by diversity of revenue sources and growing product revenue 1. Includes stock - based compensation expense of $10.5M and $10.5M in the three months ended 6/30/22 and 6/30/21, respectively, a nd $20.5M and $19.4M in the six months ended 6/30/22 and 6/30/21, respect
Slide 24: Summary of upcoming portfolio milestones
Summary of upcoming portfolio milestones EGFRex20m, EGFR exon 20 mutant. 24 Program / activity Area of focus Milestone Timing AYVAKIT Non - advanced SM Submit sNDA to FDA Q4 2022 Submit type 2 variation MAA to EMA 1H 2023 BLU - 263 Non - advanced SM Report top - line HARBOR Part 1 data Q4 2022 BLU -
Blueprint Medicines — Investor Presentation (September 2022) on 6ix